FDA’s Funding Bridle: House Demands Opioid Guidance, Limits Compounding Boost
This article was originally published in The Pink Sheet Daily
Executive Summary
Senate appears on track to fund agency without serious caveats, setting up a potentially contentious conference.
You may also be interested in...
FDA’s Regulatory Rock And Hard Place: How To Handle Draft Guidances
Republicans on the Senate HELP Committee say they are concerned that FDA is using draft guidance documents to set substantive policy, which they argue puts companies in a difficult position.
FDA Opioid Guidance Is Silent On Generics, Cautions That Addicts Can Erase Labeling
Draft guidance on abuse-deterrent opioids notes that labeling claims may be revised if abusers outwit the abuse-resistant technology; the agency’s evaluation of generic-related citizen petitions continues.
Rare Cancer Development Consortium Moving Toward Target Selection
An upcoming public meeting will include a look at platforms before the first targets are chosen.